Pfizer says former employee stole trade secrets on megablockbuster COVID-19 vaccine FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient death Federal jury holds pharmacy chains CVS, Walgreens and Walmart responsible for role in opioid crisis Elizabeth Holmes admits to OK'ing shady practices at Theranos Amid Talkspace leadership exodus and stock freefall, law firms investigating potential claims of securities violations Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet BeiGene plans to spend 'several hundred million dollars' on initial build-out of landmark US site Regulatory interaction pinpointed that could pave new pathway for treating inflammatory diseases UCB latest drugmaker to restrict 340B access to contract pharmacies Philips debuts AI-equipped MRI machines plus spectral angio-CT combination scanners Takeda's post-transplant CMV drug Livtencity, shouldering $800M in sales expectations, scores FDA nod BD snags new senior VP of investor relations from Medtronic Featured Story | By Eric Sagonowsky Pfizer and other drugmakers go to great lengths to protect their proprietary information. When it comes to the world's best-selling pharmaceutical product, the company's BioNTech-partnered COVID-19 vaccine, Pfizer's defense of trade secrets carries even more weight. That's why the company is working to get a handle on information allegedly stolen by a "soon-to-be former employee." read more |
| |
|---|
|
Top Stories By Kyle LaHucik A patient has died in a Kura Oncology phase 1b trial in people with acute myeloid leukemia leading the FDA to place a clinical hold on the study. The investigational oral treatment was potentially associated with differentiation syndrome, an adverse event that the biotech's management said is "part and parcel of this mechanism of action." read more By Heather Landi A federal jury in Cleveland on Tuesday found that three of the nation’s largest pharmacy chains, CVS, Walgreens and Walmart, were liable for contributing to the opioid epidemic in two Ohio counties. read more By Andrea Park Nearly three months into her federal trial over a dozen counts of fraud, Elizabeth Holmes took the stand last week, undergoing questioning by her defense team that has so far stretched across three days. read more By Heather Landi It's been a tumultuous two weeks for teletherapy company Talkspace as three key executives have left, its stock has tumbled and now shareholder rights law firms say they are investigating potential claims that the company's officers and directors violated federal securities laws. read more By Nick Paul Taylor Pfizer has reported top-line results on its $250 million antisense bet. The phase 2b clinical trial of the cardiovascular disease drug met its primary endpoint but, with Pfizer still considering next steps and yet to share data, it is unclear whether the asset can muscle in on a market targeted by Regeneron. read more By Joseph Keenan When BeiGene this summer laid out plans to build a "flagship" U.S. manufacturing and R&D site in New Jersey, the company kept its planned investment amount under wraps. As the project proceeds, the company now says it plans to spend hundreds of millions during the initial phase of construction. read more By Kyle LaHucik Researchers identified a molecule that interacts with the regulator of certain immune cells as a potential target to treat immune and bone metabolic diseases. The team at Tokyo University of Science found that when a ligand known as NA2 interacts with the dendritic cell regulator, the pairing is able to suppress autoimmune diseases. read more By Robert King UCB became the ninth drugmaker to cut off sales of 340B-discounted products to contract pharmacies despite an ongoing legal feud between several drugmakers and the federal government. read more By Conor Hale Philips raised the curtain on a new portfolio of smart MRI machines equipped with artificial intelligence programs to help speed up image acquisition and diagnosis as well as a new scanner combining spectral CT with real-time, image-guided therapy hardware. read more By Angus Liu Transplant patients who experience a potentially deadly viral infection that doesn’t respond to existing treatments have a new FDA-approved treatment option. For the therapy’s developer, Takeda, the approval adds another component to its growth plans in the years to come. read more By Andrea Park As it nears the halfway point of its BD2025 plan to accelerate companywide growth and stakeholder value, BD has tapped a seasoned exec from one of its competitors to oversee all investor-facing communications. read more | | Webinar: Give Your Medtech Sales a Collaboration Advantage Tuesday, November 30 | 12pm ET / 9am PT Medtech companies have long been burdened by inefficient communication between front office (sales) and back office (operations). It’s clear a new approach is needed – one that increases collaboration and communication between sales and operations, improves the customer experience, and increases revenue. Learn More. |
|
